scholarly journals External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study

2021 ◽  
Vol 10 (3) ◽  
pp. 520
Author(s):  
Francesco Foschi ◽  
Fabio Conti ◽  
Marco Domenicali ◽  
Pierluigi Giacomoni ◽  
Alberto Borghi ◽  
...  
Keyword(s):  
General Population ◽  
Fatty Liver ◽  
External Validation ◽  
Strongly Correlated ◽  
Alcoholic Fatty Liver ◽  
Fatty Liver Index ◽  
C Statistic ◽  
Hepatic Steatosis Index ◽  
The Town ◽  
Small Advantage

We externally validated the fatty liver index (FLI), the lipid accumulation product (LAP), the hepatic steatosis index (HSI), and the Zhejiang University index (ZJU) for the diagnosis of fatty liver (FL) and non-alcoholic fatty liver disease (NAFLD) in the general population. The validation was performed on 2159 citizens of the town of Bagnacavallo (Ravenna, Italy). Calibration was evaluated by calculating the calibration slope and intercept and by inspecting calibration plots; discrimination was evaluated using the c-statistic. The average calibration slope was 1 and the average intercept was 0 for all combinations of outcomes and indices. For the diagnosis of FL, the c-statistic was 0.85 for FLI, 0.83 for ZJU, 0.82 for HSI, and 0.80 for LAP; for the diagnosis of NAFLD, the c-statistic was 0.77 for FLI, 0.76 for ZJU, 0.75 for HSI, and 0.74 for LAP. All indices were strongly correlated with each other. In conclusion, FLI, LAP, HSI, and ZJU perform similarly well to diagnose FL and NAFLD in the Bagnacavallo population, even if FLI has a small advantage as discrimination is concerned.

scholarly journals Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults

Nutrients ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 522 ◽  
Author(s):  
Alejandra Cantoral ◽  
Alejandra Contreras-Manzano ◽  
Lynda Luna-Villa ◽  
Carolina Batis ◽  
Ernesto Roldán-Valadez ◽  
...  
Keyword(s):  
Young Adults ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Liver Fat ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Sweetened Beverages ◽  
Fatty Liver Index ◽  
Hepatic Steatosis Index ◽  
Sectional Analysis

Fructose intake has been associated with non-alcoholic fatty liver disease (NAFLD). The objective of this study was to assess the consumption of dietary fructose according to: 1) classification of hepatic steatosis by two indexes and 2) diagnosis of NAFLD by MRI. We conducted a cross-sectional analysis among 100 young adults from Mexico City. The Hepatic Steatosis Index (HSI) and the Fatty Liver Index (FLI) were estimated using Body Mass Index (BMI), waist circumference, and fasting concentrations of glucose, triglycerides, and hepatic enzymes (ALT, AST, GGT). A semi-quantitative food frequency questionnaire was administered to obtain dietary sources of fructose. We estimated the concordance between the hepatic indices and NAFLD and the correlation between the index scores and the percentage of liver fat. Eighteen percent presented NAFLD; 44% and 46% were classified with hepatic steatosis according to HSI and FLI, respectively. We compared dietary intake of fructose by each outcome: HSI, FLI, and NAFLD. Sugar-sweetened beverages (SSB) and juices were consumed significantly more by those with steatosis by FLI and NAFLD suggesting that SSB intake is linked to metabolic alterations that predict the risk of having NAFLD at a young age.

scholarly journals Is the Mediterranean Diet the Best Approach to NAFLD Treatment Today?

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 739
Author(s):  
Francesco Angelico ◽  
Domenico Ferro ◽  
Francesco Baratta
Keyword(s):  
Liver Disease ◽  
General Population ◽  
Fatty Liver ◽  
Mediterranean Diet ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
The Mediterranean ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent diseases worldwide, involving about 20–30% of the general population [...]

Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non‐alcoholic fatty liver disease

2018 ◽  
Vol 49 (3) ◽  
pp. 296-303 ◽  
Author(s):  
Kenichi Tanaka ◽  
Hirokazu Takahashi ◽  
Hideyuki Hyogo ◽  
Masafumi Ono ◽  
Noriko Oza ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
General Population ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Hemoglobin A1c ◽  
Epidemiological Survey ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals The association of hepatic steatosis and fibrosis with heart failure and mortality

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Jiyun Park ◽  
Gyuri Kim ◽  
Hasung Kim ◽  
Jungkuk Lee ◽  
You-Bin Lee ◽  
...  
Keyword(s):  
Heart Failure ◽  
General Population ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Patient Group ◽  
Cox Regression ◽  
Nonalcoholic Fatty Liver ◽  
Fatty Liver Index ◽  
Increased Risk ◽  
All Cause Mortality

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/or fibrosis are associated with the development of incident heart failure (iHF), hospitalized HF (hHF), mortality, and CV death in both the general population and HF patients. Methods We analyzed 778,739 individuals without HF and 7445 patients with pre-existing HF aged 40 to 80 years who underwent a national health check-up from January 2009 to December 2012. The presence of hepatic steatosis and advanced hepatic fibrosis was determined using cutoff values for fatty liver index (FLI) and BARD score. We evaluated the association of FLI or BARD score with the development of iHF, hHF, mortality and CV death using multivariable-adjusted Cox regression models. Results A total of 28,524 (3.7%) individuals in the general population and 1422 (19.1%) pre-existing HF patients developed iHF and hHF respectively. In the multivariable-adjusted model, participants with an FLI ≥ 60 were at increased risk for iHF (hazard ratio [HR], 95% confidence interval [CI], 1.30, 1.24–1.36), hHF (HR 1.54, 95% CI 1.44–1.66), all-cause mortality (HR 1.62, 95% CI 1.54–1.70), and CV mortality (HR 1.41 95% CI 1.22–1.63) in the general population and hHF (HR 1.26, 95% CI 1.21–1.54) and all-cause mortality (HR 1.54 95% CI 1.24–1.92) in the HF patient group compared with an FLI < 20. Among participants with NAFLD, advanced liver fibrosis was associated with increased risk for iHF, hHF, and all-cause mortality in the general population and all-cause mortality and CV mortality in the HF patient group (all p < 0.05). Conclusion Hepatic steatosis and/or advanced fibrosis as assessed by FLI and BARD score was significantly associated with the risk of HF and mortality.

scholarly journals Non-resolution of non-alcoholic fatty liver disease (NAFLD) among urban, adult Sri Lankans in the general population: A prospective, cohort follow-up study

PLoS ONE ◽  
2019 ◽  
Vol 14 (10) ◽  
pp. e0224474
Author(s):  
Madunil Anuk Niriella ◽  
Anuradhani Kasturiratna ◽  
Thulani Beddage ◽  
Dileepa Senajith Ediriweera ◽  
Shamila Thivanshi De Silva ◽  
...  
Keyword(s):  
Liver Disease ◽  
General Population ◽  
Fatty Liver ◽  
Prospective Cohort ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Follow Up Study ◽  
Alcoholic Fatty Liver Disease

scholarly journals Bile Acid and Fibroblast Growth Factor 19 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Sleeve Gastrectomy

2019 ◽  
Vol 8 (6) ◽  
pp. 815 ◽  
Author(s):  
Hsien-Hao Huang ◽  
Wei-Jei Lee ◽  
Shu-Chun Chen ◽  
Tung-Fang Chen ◽  
Shou-Dong Lee ◽  
...  
Keyword(s):  
Bile Acid ◽  
Fatty Liver ◽  
Bile Acids ◽  
Fatty Liver Disease ◽  
Total Bile Acid ◽  
Alcoholic Fatty Liver ◽  
Liver Index ◽  
Fatty Liver Index ◽  
Total Bile Acids ◽  
Alcoholic Fatty Liver Disease

Background: Sleeve gastrectomy (SG) is an effective treatment for obesity and type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD); however, the mechanism is not completely understood. Bile acids and fibroblast growth factors (FGFs) are involved in the regulation of energy metabolism. Methods: We investigated the roles of total bile acid and FGF 19 in T2DM remission and NAFLD improvement in obese subjects undergoing SG. A total of 18 patients with obesity and T2DM undergoing laparoscopic SG were enrolled in this study. Serial plasma total bile acid and FGF 19 levels were measured, while the fatty liver index was calculated before and after surgery. Results: The FGF 19 level significantly increased, and the total bile acid level and fatty liver index decreased 1 year after surgery. The complete T2DM remission rate was 66.7% one year after surgery; the complete remitters had significantly lower FGF 19 levels and higher insulin levels than the non-complete remitters. The complete remitters also had significantly decreased total bile acid levels and increased FGF 19 levels 1 year after surgery compared with those before surgery. The fatty improvers had significantly decreased total bile acid levels and increased FGF 19 levels 1 year after surgery compared with those before surgery. Conclusion: The total bile acids level and fatty liver index decreased, and the FGF 19 levels increased 1 year after SG. Both T2DM complete remitters and NAFLD improvers showed significantly decreased total bile acid levels and increased FGF 19 levels 1 year after SG. Plasma total bile acids and FGF 19 might have roles in T2DM remission and NAFLD improvement. Low preoperative FGF 19 levels might be a predictor for NAFLD improvement after SG.

Sign in / Sign up

Export Citation Format

Share Document